Archive for the ‘Cellceutix Corp. CTIX’ Category

Cellceutix Corp. (CTIX) Submits Abstract for American Society of Clinical Oncology Meeting

Monday, February 4th, 2013

Cellceutix is a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of small molecule drugs to treat conditions such as drug-resistant cancers and autoimmune diseases. The company’s flagship compound is an anti-cancer drug, Kevetrin.

The company announced today that it is submitting an abstract for the upcoming 2013 American Socirty of Clinical Oncology Annual Meeting, which is to be held in Chicago, May 31 to June 4. The presentation is titled “A Phase 1 Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic Study of Thioureidobutyronitrile (Kevetrin), a Novel p53 Targeted Therapy in Patients with Advanced Solid Tumors.”

The meeting will give Cellceutix an opportunity to provide a comprehensive update on the latest data from the Kevetrin clinical trials to all interested parties. The meeting will showcase the accomplishments regarding Kevetrin since it was first introduced three years ago at the American Association for Cancer Research as a drug on the frontier of cancer research. Over those few days, there will also be a chance for company executives to interact with others and discuss future collaborations and studies.

The Chief Science Officer at Cellceutix, Dr. Krishna Menon, gave a preview. Menon stated, “We are still at the early stages of the clinical trial. To date, we have not observed any dose limiting toxicities. Initial pharmacokinetic data has been received, and is consistent with the animal data, which is a very optimistic sign going forward.”

For additional information about Cellceutix and Kevetrin, please visit

Let us hear your thoughts below:

Cellceutix Corp. (CTIX.OB) Wraps Up Toxicology Studies as Human Trials Near for Kevetrin

Tuesday, August 24th, 2010

Cellceutix Corp. announced today that they have received nearly all the data regarding the toxicology studies for Kevetrin™, the Company’s flagship compound for the treatment of multi-drug-resistant cancers. The remaining data is expected within two or three weeks. This data is the final information required for the Investigational New Drug Application (IND) to be prepared and submitted to the U.S. Food and Drug Administration. In preparation for the filing, Cellceutix has engaged additional consultation to bring Kevetrin to human trials.

George Evans, CEO of Cellceutix, commented, “We are continuing to hit our targets at or ahead of schedule with Kevetrin. The pre-clinical data to date has been extremely encouraging and we expect that these final data are going to fall right into line.” Mr. Evans continued, “We are well aware of the significant impact Kevetrin can provide to patients in need if Kevetrin can perform in human trials as it has in the pre-clinical research. We are presently organizing the team for the IND and doing all possible preparation in order to submit the filing quickly once the final toxicology data is in our hands.”

“I have been closely involved in the development of several successful compounds in my 30 years in the industry and am extremely encouraged by the data that Kevetrin has produced,” stated Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. “The completion of pre-clinical studies creates a great deal of excitement for our team as we are anxious to see Kevetrin being utilized as a human therapy in the near future.”

In a recent interview on, Leo Ehrlich, CFO of Cellceutix is quoted as saying, “Our chief scientific officer, who developed our cancer drug, was a group leader of cancer research at Eli Lilly (NYSE: LLY). He was the key developer of two blockbuster cancer drugs named Alimta and Gemzar, which generate billions of dollars in sales.” The history of CEO George Evans and his extensive experience as General Counsel at Pfizer, coupled with the experiences of Dr. Menon and the rest of the Advisory Board, should make many industry leaders take notice of Cellceutix.

The pre-clinical research of Kevetrin appears to have moved smoothly and quickly with extremely promising data. In the biotechnology world, companies are very careful not to divulge too much information or makes statements that can be misleading as there is always a possibility that drugs will fail as research and testing continues. This makes complete sense from every legal aspect. But, it should not go without recognition that the team at Cellceutix has a very distinguished history.

More due diligence on Cellceutix Corporation, the compounds in the pipeline and the investment opportunity presented can be found on the Company’s website at

Let us hear your thoughts: Cellceutix Corp. Message Board

Companies Vying for Position with Psoriasis Drugs as Industry Sets to Double to Nearly $7 Billion in Next Decade

Tuesday, August 17th, 2010

Recently, Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and health care issues, released an article stating that “the continued uptake of marketed and emerging interleukin and TNF-alpha inhibitors and a twofold increase in the penetration of biologics in the moderate-to-severe population will drive the psoriasis drug market to double from $3.4 billion in 2009 to $6.8 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.”

The report went on to detail the main competitors in the psoriasis market which include:

• Enbrel (etanercept), a TNF-alpha inhibitor (Amgen/GlaxoSmithKline/ Pfizer/Takeda)
• Humira (adalimumab), an interleukin inhibitor (Abbott/Eisai)
• Stelara (ustekinumab), an interleukin inhibitor(Johnson & Johnson/ Centocor Ortho Biotech)
• Briakinumab, an interleukin inhibitor (Abbott)

Enbrel was the clear leader in 2009 with over $1.3 billion in sales, but it should be noted that Humira and other interleukin inhibitors are expected to provide stiff competition in 2010 and beyond. Newly USFDA-approved Stelara (approved in January 2010) is also expected to climb to the top of the ranks and cut into Enbrel’s market share as one head to head test showed Stelara to be more effective than Enbrel.

“In 2011, Humira will overtake Enbrel as the new market leader with blockbuster sales of $2.3 billion by 2019—nearly double that of Enbrel’s sales in that year,” said Decision Resources Analyst Iva Holder, Ph.D. “The interleukin inhibitor Stelara, which launched last year, will rank third in 2019, garnering approximately $970 million in sales. Additionally, briakinumab—the most promising interleukin inhibitor, is poised to compete for first-line biologic use and its sales will exceed $800 million in 2019.”

An interesting conclusion to the article stated that no oral agents were expected to have a significant impact on the psoriasis drug market in the next decade. An effective oral agent is generally thought of to be the “holy grail” in biotechnology because of the ease of use. Many notable companies will be anxious to prove the Pharmacor 2010 findings wrong with their oral medications in development for psoriasis. Pharmas such as Genzyme, Bristol-Myers Squibb and Novartis all have oral drugs in development at the moment.

A true sleeper in the industry is Cellceutix Corporation, which trades on the Bulletin Boards under the ticker CTIX. Their compound, KM-133, has displayed promising results in early research and has carries the possibility of a 505(b)(2) exemption which would move it directly into Phase II clinical trials and put Cellceutix in a prime position amongst industry giants. Destum Partners has just begun actively pursuing a developmental partner for KM-133 for Cellceutix. The Cellceutix executives believe that the combination of exemption possibility and the strong results already exhibited will be very appealing to large pharmas for development. Destum has spoken with several companies already and will be reporting on progress in the near future.

Let us hear your thoughts: Cellceutix Corp. Message Board

Autism’s New Hope

Wednesday, August 11th, 2010

For a parent, it’s difficult to imagine a more distressing disease than autism, nor one that has caused more of an outcry for a remedy given its dramatic increase in diagnosis since the 1980s. Autism is a neural development disorder, greatly impairing the sufferer’s ability to communicate or interact socially. It affects the way nerve cells in the brain and their synapses connect and organize, often displaying signs before the age of two, robbing a child of normal parental or peer relations.

There is a strong genetic basis to autism, but the exact nature of the mechanism is unclear. A variety of external influences have been proposed as contributors, such as heavy metals, pesticides, and even childhood vaccines, but nothing has been proven. Evidence suggests that the brain is altered soon after conception, causing a number of things to occur, some of which could be affected by environmental factors. It is known that the brains of autistic children often grow faster immediately after birth, later slowing to normal or subnormal rates. But autism is increasingly believed to be a complex disorder involving multiple causes.

Whatever the source, the disease is known to strike just over half of 1% of the general population, and is four times more common in males than females. Although the number of people diagnosed with autism has greatly increased in the past few decades, it is not clear whether this reflects actual prevalence or simply changes in diagnostic practice. Most importantly, there is no known preventative or cure. Psychological and behavioral based interventions may help, but there is little hard evidence to support such treatments.

Although no currently available medication relieves autism’s core social and communication impairments, there are a number of medications used to treat some of the symptoms associated with autism, such as antidepressants, stimulants, and antipsychotics, but individual response to such drugs can vary greatly. Below are some of the publicly traded pharmaceutical companies currently producing drugs for treating autism.

Johnson & Johnson (NYSE: JNJ) – Risperdal is an antipsychotic medication used to treat autistic disorders, specifically irritability common in autistic children and teenagers. Risperdal is the only FDA approved drug specifically cited as a treatment for autism, but is the subject of much controversy as to its effectiveness and debate over giving children antipsychotic medication.

Eli Lilly & Company (NYSE: LLY) – Prozac, the popular antidepressant, is used for both depression and obsessive compulsive disorder in autistic children over the age of 7.

Novartis AG (NYSE: NVS) – Ritalin, the well-known psychostimulant drug used to treat attention-deficit hyperactivity disorder, has also been used to treat autism symptoms, and is now commonly available in time release form.

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) – Adderall XR is another extended-release drug used to help with attention and focus problems in people with autism, and is also produced by Shire plc (SHPGY).

Cellceutix Corporation (OTCBB: CTIX) is an up-and-coming company that perhaps offers the greatest and most recent hope in the treatment of autism with its compound, KM-391. This compound, unlike all of the other treatments, is 100% novel, designed to go after the core issues of autism, not just the resulting symptoms. Animal tests have shown a significant increase in serotonin uptake and increases in brain plasticity compared to controls, resulting in both physical and behavioral changes. The company is expediting further testing based upon initial research and strong public response. In addition to this very important development for the potential treatment of autism, Cellceutix is approaching phase 1 clinical trials for KevetrinTM, a promising compound for the treatment of drug-resistant cancers.

The company’s success in the field of autism, and also cancer, can be largely attributed to the fact that officers and advisors include leading pioneers in the fields of genetics and cancer. Cellceutix is now being visited by major companies in the world of pharmaceuticals and finance.

Let us hear your thoughts: Cellceutix Corp. Message Board

Cellceutix Corporation (CTIX.OB) Pursuing Multi-Billion Dollar Psoriasis Treatment Market; Company Continues Push to Develop Compounds

Wednesday, August 4th, 2010

Cellceutix Corporation is not a company standing still. The emerging biotech has 8 compounds in their portfolio, with two of them being actively developed by the Company. Kevetrin, Cellceutix’s lead compound is in development for the treatment of multi-drug resistant cancers and is rapidly approaching human trials as the IND filing with the FDA is being prepared. KM-391 has already garnered industry attention as it is being developed to address the core issues of autism.

Constantly moving forward, Cellceutix announced in late July that they have retained Destum Partners to identify and secure a developmental partner for another very promising compound in their portfolio. KM-133 has already undergone some preclinical testing as a new treatment for psoriasis. Cellceutix believes that KM-133 will have industry appeal in targeting a partner due to preclinical results, industry growth and the fact that KM-133 may qualify for an exemption that allows it to forgo more Phase I trials and move directly into Phase II human trials.

One particular test compared KM-133 to methotrexate, which is commonly used today to treat severe psoriasis. The testing was done through human xenografts, which are the grafting of human skin affected by psoriasis onto an animal, in this case, mice. Throughout the course of the entire 6 months of the experiment, the animals treated with KM-133 demonstrated no recurrence of psoriasis lesions, while the animals treated with methotrexate had lesions reappear in 61 days.

In 2010 an estimated 18 million people in the 7 major markets suffered from Psoriasis. Estimates worldwide put the number as high as 125 million people being affected. The revenues generated from the treatment of the disease were approaching in $3 billion in 2008 alone. . While estimates vary, according to a report from Global Industry Analysts, Inc., the global psoriasis drugs market is estimated to exceed $7.3 billion by 2015. There are very few drugs on the market today that treat psoriasis exclusively. Enbrel, for example, treats both psoriasis and rheumatoid arthritis and is marketed by Pfizer (NYSE: PFE) and Amgen (NASDAQ: AMGN). A drug uniquely for psoriasis opens up lucrative market potential with the successful development of KM-133.

There is a FDA rule, termed “Rule 505(b) (2)”, that permits the bypassing pre-clinical testing if the active ingredient in a compound has previously been approved by the FDA. Due to the chemical base of KM-133, it has the potential of this rule being applicable, thus saving a great deal of time and money by moving directly into human trials.
The website for the National Psoriasis Foundation has 11 oral drugs in development presently. If KM-133 is approved for the 505 exemption, it will be right in the mix as 10 of the 11 drugs are presently in Phase II clinical trials. With these facts in mind, it is understandable why Cellceutix has taken the progressive approach with contracting Destum to bring further development of KM-133 to fruition.

CTIX is still a “sleeper” in the stock market world, but certainly portrays many of the qualities of a biotech that could explode upon news. Led by CEO George Evans and his more than 25 years as an executive for pharma giant Pfizer, including ending his career as General Counsel for the worldwide prescription drug unit, Cellceutix may soon be appearing on more biotech investor’s radar as they continue to push forward with development of their compounds.

More information on Cellceutix, their compounds and the investment opportunity they present can be found on the CTIX website at

Let us hear your thoughts: Cellceutix Corp. Message Board

Strength of Cellceutix, Inc. (CTIX.OB) Pipeline Results in Contracting of Destum Partners to Partner Psoriasis Compound

Monday, July 26th, 2010

Cellceutix Corporation announced this morning that they have contracted acclaimed consulting firm, Destum Partners, to aggressively seek a partner to develop their compound, KM-133, for the treatment of psoriasis. Destum has a distinguished history of establishing partnerships in the biotechnology industry to meet the developmental needs for promising compounds.

Cellceutix has been receiving notoriety recently with a series of press releases regarding Kevetrin, their compound in development for multi-drug resistant cancers, and KM-391, their compound for the treatment of the core issues of autism. Kevetrin is approaching Phase I human trials and has displayed extremely promising results in pre-clinical studies. As a result, major pharma and financial institutions have recently contacted Cellceutix to learn more about the Company and the promising cancer compound that it possesses. In the area of autism research, Cellceutix stands amongst the top of industry leaders, big and small, as they have already conducted several pre-clinical studies on KM-391 with very promising data being compiled.

Interestingly, and also akin to the overall Cellceutix business philosophy, Cellceutix has maintained a very “low-key” approach to the development of their compound for psoriasis. While many small biotechs would be publishing news regularly on a compound of this nature and potential, the Cellceutix management team has been carefully deliberating over the most effective way to continue the development of KM-133 to support shareholder value and financial responsibility of the Cellceutix budget.

In a conversation with Leo Ehrlich, Chief Financial Officer of Cellceutix, we questioned what other options were available for the development of KM-133. Mr. Ehrlich explained that not only could Cellceutix develop the compound on their own, but that they had recently been contacted by officials from the Vietnamese government. The Vietnamese see extremely promising potential in KM-133 and as they wish to establish themselves as a world-leader in the area of medical tourism, they see value in the development of KM-133 in their country as a possible opportunity to launch this initiative. The Cellceutix management spent many hours in discussions about all avenues and decided that partnering for the development was the best course of action for its shareholders.

In a video that can be viewed on the Cellceutix website at, CEO George Evans states that, “it is really an embarrassment of riches” as the Company knows the potential of KM-133, yet is focused heavily on the development of Kevetrin and KM-391. In the press release this morning, Mr. Evans explains, “This decision is ultimately a consequence of the strength of our pipeline.” He continued, “With our primary focus on the impending IND filing for Kevetrin™ and our work on KM-391 for autism, our board determined that this approach is the best way to increase value for our shareholders. We selected Destum because of their deep experience in the dermatology space and their excellent recent track record in concluding development deals.”

The data from results of testing already completed for KM-133 has been extremely promising. In a human xenograft animal model of psoriasis, KM-133 reduced psoriasis significantly more than controls. Psoriasis did not recur with KM-133 during the entire 180 day course of the experiment, whereas psoriasis reoccurred in the groups treated with methotrexate, a drug commonly used for the treatment of severe psoriasis, after an average of 61 days. The effectiveness demonstrated by KM-133 in these studies, if confirmed in human trials, would position the compound in a very large market.

According to a report published by Research and Markets, the psoriasis market for the seven major markets in 2008 was $2.5 billion and is projected to grow at a compound annual growth rate of 3.4% through 2018. According to the National Institutes of Health (NIH), as many as 7.5 million Americans (125 million worldwide) have psoriasis making it one of the most prevalent autoimmune diseases in the U.S. affecting all ages of both sexes.

In addition, KM-133 may be eligible for an abridged FDA approval process that would allow the compound to go directly into human trials. The rule, 505(b)(2), permits compounds with an active ingredient that has previously been approved by the Food and Drug Administration to forego pre-clinical testing. Knowing that this rule has saved companies millions of dollars and significant time, Cellceutix believes that this fact, coupled with the promising data already compiled, will make KM-133 very appealing for development with a partnering company.

Gareth Lugg, Managing Director and Co-Founder of Destum Partners commented, “We are very pleased that Cellceutix selected us for this project. Although Cellceutix is a small company, the strength of their compounds in development is extraordinary.” Mr. Lugg continued, “Our extensive experience in the dermatological industry has us very bullish on the partnership potential for this compound.”

Destum Partners has extensive advisory experience both in the dermatology and autoimmune therapeutic areas. They have worked with companies such as Collagenex and Pfizer specifically focused on dermatology. Most recently, Destum Partners completed a partnering agreement on behalf of Diamyd Medical AB with OMJPI a division of Johnson and Johnson for the treatment and prevention of Type I Diabetes — an autoimmune disease. Diamyd received an upfront payment of US $45 million, and has the potential to receive US $580 million in milestone payments.

Once again, this “under the radar” company has brought significant news to the table about another one of the eight compounds in their portfolio. More information about Cellceutix, their compounds and the investment opportunity that they possess can be found on their corporate website at

Let us hear your thoughts: Cellceutix Corp. Message Board

Cellceutix Corp. (CTIX.OB) Offers Hope to Cancer Industry and Opportunity to Investment Community

Tuesday, July 20th, 2010

Lung cancer is still the number one cause of cancer death among men and women in the United States. Projections for 2010 by the American Cancer Society include over 220,000 new cases of lung and bronchial cancers with nearly 160,000 deaths as a result of lung cancer. If projections hold true, the number of new cases will be greater than the 173,770 cases that were reported in 2004. Another interesting fact is that, while leveling in the last several years, the number of deaths among women attributed to lung cancer has not seen a significant decline with the other major lines of cancer since 1990. Projections for 2010 have the number of deaths in women from lung cancer being approximately 10% greater than breast, colon and rectum cancers combined.

Lung carcinomas have proven to be very resilient with a great ability to adapt to chemotherapy treatments and still present a great area of need for new therapies. Multi-drug resistance, the principal mechanism by which many carcinoma strains develop resistance to chemotherapy drugs, is one of the primary reasons for ineffectiveness of standard cancer therapies on the market today. Cellceutix Corporation (CTIX.OB) trades on the NASDAQ Bulletin Board in the area of $.60 per share and is making significant strides with Kevetrin, their lead compound in development for treatment of multi-drug resistant cancer strains of the lung, breast and colon. Cellceutix is compiling the final data from pre-clinical toxicology studies to file an Investigational New Drug (IND) application with the USFDA in preparation for human trials of Kevetrin. Cellceutix plans to ask for the application to be “fast tracked” to expedite the procedure.

Cellceutix has developed and researched Kevetrin from the ground up with very promising results in pre-clinical studies. The latest pharmacology studies were released last week with the data coinciding with all other previous research. Kevetrin has already received accolades from posters being presented by Cellceutix at the American Association for Cancer Research (AACR). The AACR is considered by most to be the leading institute for cancer research in the world today. A poster on Kevetrin was highlighted at the AACR’s “Frontiers in Basic Cancer Research Meeting” in Philadelphia in October 2009. Research on Kevetrin has demonstrated success in more than 5,000 small animal tests, achieving significant delays in tumor growth compared to controls in multi-drug resistant lung, breast and colon cancer cell lines. The data also showed that a second cycle of Kevetrin continued to delay tumor growth without any development of resistance.

From an investment standpoint, Cellceutix has a very low market cap of around $40 million. There is a large insider holding ratio (approximately 50%) and a low float of approximately 40 million shares available for free trading. The Cellceutix management has been primarily funding operations independently without dilution of the share structure. It is apparent that they feel strongly their company’s compounds can reap great rewards in the future.

Leo Ehrlich, Chief Financial Officer of Cellceutix, stated, “When talking about a successful approved drug for resistant cancers, you must realize that you are talking about revenue possibilities into the billions of dollars. Presently, this is one of the most sought areas of drug development or acquisition by big pharma. ”

Mr. Ehrlich said, “Just over the last month we were contacted and invited by a major pharmaceutical company and a major financial institution interested in learning more about Cellceutix. Nothing is ever a complete certainty, but we anticipate continued success and the true value of our company to continue to be realized.”

The CTIX price per share has been steadily increasing this year with a 2010 low of $.20 and presently trading at $.66. To learn more about Cellceutix, Kevetrin and the investment opportunity Cellceutix presents, please visit the Cellceutix website at

Let us hear your thoughts: Cellceutix Corp. Message Board

Industry Attention Turning to Cellceutix Corp. (CTIX.OB) as a Result of Cancer and Autism Research

Monday, July 12th, 2010

Since Cellceutix began researching and developing Kevetrin for the treatment of multi-drug resistant cancers, the company’s management team knew that they were on to something with great potential. At first, Kevetrin started as a compound that was being developed for head and neck cancers, but when it was discovered in pre-clinical trials that it could possibly be an effective chemotherapy treatment for strains of cancer that we non-responsive to standard therapies today, the realm of humanitarian and shareholder benefits greatly increased.

The pre-clinical research required to file an Investigational New Drug (IND) application with the FDA has now been concluded on Kevetrin with the data from the toxicology studies being compiled presently to prepare the IND. The pre-clinical data has been very promising throughout the year-long research process and now Cellceutix is ready to take Kevetrin research to the next level, human trials. In the world of biotechnology, many companies have cancer compounds in development, but Cellceutix has something unique as Kevetrin is a 100% novel compound and is designed to provide a treatment for areas of chemotherapy where there is presently a void.

Combine the pre-clinical data and the proximity of human trials with the targeted market for Kevetrin and it is easy to see why Cellceutix has been receiving so many phone calls. In a press release from Cellceutix earlier this week, Chief Financial Officer, Leo Ehrlich, commented, “In the last few weeks, we have been visited by a major financial institution wanting to learn more about Cellceutix, as well as meeting with one of the world’s largest Pharmas who too wished to learn more about Cellceutix.” While the focus of the press release was on more positive data for Kevetrin, this portion of the press release certainly merits revisiting from an investing standpoint.

Large Pharma is notoriously bad at research and development of their own drugs as the trend has shifted to purchasing compounds from smaller biotechs or purchasing the company entirely when they have compounds with solid possibilities of generating large revenues. It is no secret that a successful cancer drug of Kevetrin’s nature can produce phenomenal revenues. Dr. Krishna Menon, Chief Scientific Officer of Cellceutix, has already been a part of this process as he played a key role during his tenure at Eli Lilly (NYSE: LLY, $35.12/share) in lead selection and pre-clinical development of Gemzar and Alimta, which had over $2 billion dollars in sales in 2006 alone, and is a co-developer of another seven compounds currently in late-stage clinical development. CEO George Evans certainly is aware of the possibilities after spending 25 years in executive positions at Pfizer, Inc., ending his time there as General Counsel for the worldwide prescription drug unit.

Most small biotechnology companies would be excited to have Kevetrin by itself, but Cellceutix has also established itself as an industry leader in autism research. Recent research has shown that autistic brains share similar characteristic with respect to serotonin levels and plasticity. This has been documented through a culmination of research by several reputable institutions, but a central problem in the industry has been identifying a reliable animal model. Cellceutix is one of the first to overcome that obstacle and has already conducted several pre-clinical studies with very promising early results in animal models for not only physical brain attributes, but also with behavioral traits that typically accompany autism.

The autism compound, KM-391, is bringing attention to Cellceutix not only from the investment community, but also from the general population. Cellceutix recently announced that they have drawn upon their resources to expedite the development of KM-391 due to the public support they are receiving as there is not a single drug on the market today approved as an autism treatment for all ages. To say that Cellceutix is still early in this research would be accurate as human trials are still probably a year away, but given the fact that they are one of the only companies in the world with a novel compound being developed for the treatment of the core issues of autism puts them ahead of the rest of the field.

In the biotechnology world, the possibilities are endless when you develop a successful compound. For a developmental biotech, the struggles can be great, but the rewards can be even greater, especially if you have multiple compounds that are producing promising data. There is a good reason why large pharmas and financial institutions are beginning to focus on Cellceutix.

More information of Cellceutix, their compounds and the investment opportunity they present can be found on the Company’s website at

Let us hear your thoughts: Cellceutix Corp. Message Board

Cellceutix Corp. (CTIX.OB) Video Chart for Monday, July 12, 2010

Monday, July 12th, 2010

The CTIX chart has become very bullish over the last couple weeks. In order to analyze thinly-traded stock charts, it is necessary to look at them from a couple different perspectives. This video explains what we see and what we are looking for in the future.

Please click the following link:

Let us hear your thoughts below:

Cellceutix Corp. (CTIX.OB) Announces Completion of All Three Animal Safety Pharmacology Studies Required by FDA Prior to Filing Investigational New Drug (IND) Application

Wednesday, July 7th, 2010

Cellceutix Corp. announced earlier this morning that it has completed all three animal safety pharmacology studies for its cancer compound, Kevetrin™, that are required by the U. S. Food and Drug Administration prior to filing an IND. These studies evaluate the impact of the administration of a compound on the respiratory, cardiovascular, and central nervous systems.

Dr. Krishna Menon, Chief Scientific Officer of Cellceutix, commented, “Previous required testing on the respiratory and central nervous systems showed no significant neuropharmacological or biologically relevant effects. This set of cardiovascular testing coincided with those results with no significant effects at low, medium or high dosage levels. While there was a transient increase in heart rate at extreme dosage levels, we do not believe it will be of any significance going forward as even the highest dosages had no toxicological effects on ECG or cardiac rhythm.” Dr. Menon continued, “The completion of animal safety pharmacology studies presents a big milestone for Cellceutix. The remaining toxicology data necessary for preparing our IND should be received by late July.”

Multi-drug resistance is one of the primary reasons standard cancer therapies can be ineffective during treatment. Treatments that were once effective at destroying cancer cells are now useless in some cases due to specific strains of cancer cells that have mutated to be resistant to today’s chemotherapy treatments. Kevetrin, a completely novel compound, is being developed by Cellceutix as a possible solution for several strains of lung, breast and colon cancers that are resistant to the chemotherapy drugs presently available.

“The completion of these studies is a giant step forward,” stated Leo Ehrlich, CFO of Cellceutix. “We are excited to have advanced Kevetrin so far so fast while also developing our other compounds, especially KM-391 for autism. In the last few weeks, we have been visited by a major financial institution wanting to learn more about Cellceutix, as well as meeting with one of the world’s largest Pharmas who too wished to learn more about Cellceutix. We are excited that we are now attracting industry attention. I believe this is the start of an exciting time for our Cellceutix team and shareholders.”

Let us hear your thoughts: Cellceutix Corp. Message Board

Cellceutix Corp. (CTIX.OB) Backed by Seasoned Management Team

Tuesday, June 29th, 2010

Cellceutix Corp. develops small molecule therapies for treatment of cancer, autism and inflammatory disease. The company is supported by a panel of officers and advisors with extensive experience and knowledge in the fields of cancer and genetics, as well as with wide experience in the pharmaceutical business and relative researching, developing and marketing.

Most of the company’s efforts center on the company’s lead product Kevetrin, which is in development for drug-resistant cancers. Cellceutix is concluding final studies before applying for FDA approval for human studies. The company’s focus is maintained by a strong management team and a shared commitment to develop treatments for today’s most challenging diseases.

Cellceutix is headed by chairman of the board and CEO George W. Evans, JD, MBA. Mr. Evans has worked in the pharmaceutical industry for more than 25 years, including several senior executive positions for Pfizer Inc. (NYSE: PFE) as general counsel for Pfizer’s global prescription drug unit, and a member of the unit’s leadership team. Mr. Evans’ experience spans a wide range of aspects in the pharmaceutical industry, including early-stage research to end-of-life cycle strategies and involvement in several mergers and acquisitions.

Dr. Krishna Menon, PhD, VMD, serves as Cellceutix’s president, chief scientific officer, and member of the company’s board of directors. Dr. Menon has more than 25 years of experience in drug development for academia and industry. As a veterinarian surgeon, Dr. Menon’s career started with his role as senior government veterinarian for a major parish in Jamaica. For two years he was director of agriculture for the Cayman Islands in the British Caribbean. Dr. Menon’s previous work includes anti-folate therapies for various cancers, research associate at Harvard University, and research scientist at In Vivo Research. After operating his own veterinary oncology and drug development consultancy practice, Dr. Menon served as group leader for Cancer In Vivo Research and Clinical Development for Eli Lilly & Co. (NYSE: LLY) where he was lead researcher for the blockbuster drugs Alimta and Gemzar.

Leo Ehrlich, CPA, has served as Cellceutix CFO since June 2007, and currently serves on the company’s board of directors. Mr. Ehrlich was previously director at StatSureDiagnostic Systems Inc., and has held various executive positions for large corporations including being a founder of NanoViricides in which his tenure saw the price per share rise from $.10 to $4.00.

For more information visit

Let us hear your thoughts: Cellceutix Corp. Message Board

Cellceutix Corp. (CTIX.OB) Autism Study Shows Increase in Serotonin Levels in Three Areas of the Brain

Thursday, June 24th, 2010

Cellceutix Corp. announced yesterday after the closing bell that they have completed another study in the research of KM-391, the company’s novel compound being developed to treat the core symptoms of autism. Pioneering research in autism treatments, Cellceutix has been making solid progress with pre-clinical research as announced in previous press releases.

In the autistic brain, neonatal serotonin depletion and decreased brain plasticity are observed. The Cellceutix team has identified a reliable animal model and has been successful in chemically inducing these characteristics in the model. The data collected to this point has been promising as KM-391 has shown to be successful in altering the serotonin and brain plasticity levels resulting in physical and behavioral changes in the model that are similar to the “non-autistic” control groups.

Cellceutix’s latest research involved physical measurements of serotonin levels in the cerebral cortex, hippocampus, and caudate nucleus areas of the brain. Several groups of animals were established with two of the groups being injected to induce the symptoms of autism. After 48 days, the brains were assayed for serotonin by ELISA with the data showing that the administration of KM-391 significantly increased serotonin levels in all 3 regions of the brain: cerebral cortex, hippocampus, and caudate nucleus, from very low levels as observed with the induced autism to normal levels as observed in placebo treated control which received no treatment.

George Evans, Cellceutix Chief Executive Officer, stated, “This new data is highly relevant as it reinforces the data from previous studies and further solidifies our contention that serotonin levels in multiple brain regions may be a necessary key to the next generation of autism treatments.”

More detailed information on Cellceutix and the progress of their research is available at

Let us hear your thoughts: Cellceutix Corp. Message Board

Cellceutix Corp. (CTIX.OB) Research on Kevetrin Showing More Great Results in Destroying Cancer Cells

Monday, June 21st, 2010

Cellceutix announced more research data this morning on studies done with Kevetrin™, their leading compound for the treatment of specific stains of multi-drug resistant breast, lung and colon cancers. This series of testing was focused on Kevetrin affecting the life cycle of a specific lung cancer cell and was conducted by the Cellceutix research team at a major cancer hospital in Boston.

The data revealed that Kevetrin had a 78% effective rate of G2/M arrest and a 66% increase in apoptosis. To understand the significance of this data, it is important to know what portion of a cell’s life cycle this is targeting. The G2/M phase of the cycle is the area right before a cell enters mitosis, which is when the cell divides into two identical nuclei. It is clear that this is a critical time because treatments are designed by definition to stop the cells from further growth. Kevetrin demonstrated nearly 80% effectiveness with regards to the specific lung carcinoma cells in stopping the cell from entering the mitosis phase.

Apoptosis is defined as a specific form of programmed cell death without releasing harmful substances into the surrounding area. Kevetrin showed a great impact on the cancer cells with a 66% increase in apoptosis meaning that it is successfully killing the carcinoma cell without damaging the healthy cells around it. Efficient treatment of cancer cells is evolving into attacking the cells from multiple pathways rather than from simply one direction. The latest research demonstrates another pathway that Kevetrin is effective and coincides with previous studies that have shown other pathways that Kevetrin showed significant methods of action in slowing or stopping cancer cell growth.

Multi-drug resistant strains of cancers are becoming more prevalent in the world today. Cancer cells are very adept at modifying themselves to resist standard therapies. As this continues to be an issue in the cancer treatment industry, the need for new treatments continues to rise to combat these strains of cancer. Kevetrin is showing in pre-clinical studies that it could be a viable answer for this unmet need. Cellceutix is in late-stage pre-clinical trials and preparing for their IND filing for Kevetrin with the FDA. The filing is scheduled to be completed in the third quarter, which starts in ten days, with human trials targeted to commence in the fourth quarter of this year.

George Evans, CEO of Cellceutix, commented, “This data provides important insight into how Kevetrin is working to attack resistant cancer cells and significant because when dealing with drug-resistant cancers it is imperative to find multiple pathways to destroy the cells.” Mr. Evans continued, “We are very excited about the potential Kevetrin is presenting to the value of our company as all pre-clinical data has been extremely promising.”

More information on Cellceutix’s revolutionary compounds and the investment opportunity that they present can be found on the corporate website at

Let us hear your thoughts: Cellceutix Corp. Message Board

Cellceutix Corp. (CTIX.OB): The Baby Blue Chip Presents a Great Investment Opportunity

Friday, June 18th, 2010

With over four thousand NASDAQ Bulletin Board listed companies, it can be a bit of a task to research and find the true jewels that present great investment opportunities. No need to keep looking as we are bringing you one today. Cellceutix Corporation trades on the NASDAQ Bulletin Board under the ticker CTIX and is emerging as an industry leader in both autism and multi-drug resistant cancers. When finding a solid biotechnology investment, it is imperative to research three primary requirements: history, pipeline and potential. We will take a look at these three and how Cellceutix Corporation measures up as an investment.


Cellceutix management is comprised of executives and an advisory board that together have well over 100 years of high-level experience in the biotechnology field. CEO George Evans ended his tenure at Pfizer as Lead Counsel of the Pharma Division, which accounts for approximately 96% of all revenues generated by Pfizer. Chief Scientific Officer, Dr. Krishna Menon, has a long and distinguished history of over 40 years in the industry. Just a few of his accolades have included being the lead researcher for the multi-billion dollar blockbuster drugs, Alimta and Gemzar, and being a recipient of the President’s Award while at Eli Lilly. CFO, Leo Ehrlich, was a founder of NanoViricides and integral to the stock price moving from $.10 to $4.00 during his tenure. The Advisory Board includes pioneers in the biotechnology field with too many distinguished awards to even begin writing them all down. Clearly, Cellceutix meets this first requirement of a great investment opportunity.


Too many biotechs have only one drug that they are developing. This “all or nothing” practice does not yield a solid investment opportunity. If that drug fails in any trials, the price per share will plummet and the company will have to spend years trying to regroup. It is important to find a company that has a strong pipeline of compounds that can be coupled with a strong research team (as described above). Also, the compounds need to be focused in an area that is not flooded by companies all trying to develop drugs for the same illness.

Cellceutix has a portfolio of 8 promising compounds with two currently in development and producing great pre-clinical results that have little competition within the industry. Kevetrin, their compound for multi-drug resistant cancers, is rapidly approaching Phase 1 human trials. Kevetrin is unlike other cancer drugs in that it is targeting specific lines of breast, lung and colon cancers that have proven to be resistant to standard drugs available on the market today. Pre-clinical studies have been concluded with Phase 1 trials targeting initiation in the 4th quarter this year.

Additionally, Cellceutix is one of only a few companies that are pursuing a treatment to address the core symptoms of autism. Pfizer and Novartis recently announced that they have begun research in this area of unmet need, but they are merely taking existing drugs and re-applying them towards autism. Cellceutix’s KM-391 is a 100% novel compound that they are developing to treat core brain issues of autism. Again, pre-clinical studies are proving very promising. If successful, KM-391 will revolutionize autism treatments.


Potential means ability to generate revenues. This directly correlates with the drugs in the pipeline and how vast the market is for them. It also incorporates the idea of becoming a potential target for acquisition by a large pharmaceutical company. It is no big secret that Big Pharma is often lacking in research lately as the pattern of simply acquiring a smaller pharma and their compounds has become the trend of choice anymore. Cellceutix is dripping with potential in both of these areas.

By selecting Kevetrin and KM-391 to be the first compounds that they develop, Cellceutix is addressing areas that will be extremely lucrative with successful progression of clinical trials. The fact is that the production of a revolutionary treatment can generate revenues into the BILLIONS of dollars. CEO George Evans is also a wizard at mergers and acquisitions through his experience at Pfizer and maintains contacts with high level executives throughout the industry. Toss in the proven track record of the research team and advisory board and Cellceutix is a company that has potential unlike any other company trading on the NASDAQ Bulletin Boards.

There you have it. Cellceutix Corporation presents an excellent investment opportunity that is sliding under the radar of investors, but will not be much longer. Big Pharma is honing in on them already and they are starting to receive an influx of attention throughout the industry. Don’t miss out on this story.

Learn more about Cellceutix Corp. and view clinical research and corporate information at

Let us hear your thoughts: Cellceutix Corp. Message Board

Cellceutix Corp. (CTIX.OB) Emerging as Industry Leader with Autism and Multi-Drug Resistant Cancer Compounds

Friday, June 11th, 2010

Cellceutix Corporation, based in Beverly, MA, has been receiving a lot of attention recently with the developments of two of their very special compounds. Cellceutix focuses their attention on the development of small molecules for unmet needs in the field of biotechnology. “Unmet needs” can mean a couple different things. One, it can mean that there is no drug on the market today that approaches a treatment for an illness from a certain clinical perspective. Second, it can mean that the present drugs available are becoming ineffective as cells can develop what is referred to as “resistance” to the standard treatments. Remember that cells are capable of regenerating and mutating. Cancer cells, in particular, are extremely adept at developing high levels of resistance making the need for new therapies to be developed to combat the illness.

Cellceutix has identified two large areas with a great need for new, revolutionary drugs. They are developing their compound, KM-391, as a treatment for autism. The Company acquired the rights to KM-391 late in 2009 and has had very promising pre-clinical test results to this point. What makes this the most unique compound being developed for autism today is that it addresses autism at its core. There are plenty of drugs on the market today that treat the symptoms that result from having autism, but there is nothing available that attempts to treat autism at the root cause.

Being that autism is a “spectrum disorder,” a great challenge is present. It is a biotechnology fact that an autistic brain has specific characteristics with regards to serotonin levels and brain plasticity that differ from a normally functioning brain. These facts are the basis of the research. Early testing has shown very promising results and as these results have been disclosed to the public, Cellceutix has been the recipient of countless phone calls, emails and other correspondences from around the country from the general public, industry leaders and the media requesting more information and expressing a great interest in seeing further development of KM-391. Earlier this week, Cellceutix issued a press release stating that they have responded to the public outcries and have drawn upon its resources to expedite pre-clinical testing of KM-391. Significant amounts of time have been eliminated through cooperative efforts from prestigious institutions to modify schedules in order to accommodate KM-391 research.

Kevetrin™, Cellceutix’s flagship compound, is closing in on Phase 1 Clinical Trials in humans. The final stages of pre-clinical research are complete with the data being evaluated now for formal presentation. Once this is complete, an Investigational New Drug (IND) application can be filed with the United States Food and Drug Administration (FDA). Phase 1 trials will then follow and hopefully will be underway in the fourth quarter of this year. Kevetrin, like KM-391, is a 100% novel compound. Most drugs on the market today are merely derivatives of existing compounds, but Kevetrin and KM-391 are completely unique.

Kevetrin is being developed to treat specific strains of lung, breast and colon cancers that demonstrate resistance to multiple drugs on the market today. Pre-clinical animal testing has shown to significantly delay tumor growth. Efficacy, the capacity to produce a desired effect, increased with increasing dosage in the studies. Kevetrin has received acclaims already due to the research conducted by Cellceutix. The American Association for Cancer Research, widely considered by many to be the premier cancer research association in the world, dubbed Kevetrin as on the “frontier of cancer research.”

So what does the future hold for Cellceutix, its compounds and its shareholders? Every developmental biotech has certain levels of speculation, but Cellceutix is a standout from the others. Their management team is led by CEO George Evans, who spent 25 years at Pfizer, ending his tenure as general counsel for the pharma division. Their research team is headed up by President and Chief Scientific Officer, Dr. Krishna Menon, who while at Eli Lilly oversaw the development of the two blockbuster cancer drugs that still produce billions of dollars in revenues. Leo Ehrlich, Chief Financial Officer of Cellceutix, has a track record of holding key executive positions in the development of small companies, including his time at NanoViricides that saw the stock price move from $.10 to $4.00.

The Cellceutix Scientific Advisory Board consists of world-renown pioneers in oncology, genetics and compound development. It is no big secret that major pharmas often look to smaller companies, such as Cellceutix, when a novel compound is developed and shows success in human studies. Nor is it a secret about the lucrative amounts of money that are offered from a large biotech to purchase a smaller biotech that has the rights to a successful new drug. The numbers are often into the billions of dollars because of the possible revenues that can be generated. Coupling the strength of the management and research team with the promising data being compiled from pre-clinical research on both Kevetrin and KM-391 and then mixing in the possibilities of revenues that can be generated, it is no wonder that Cellceutix is starting to have a lot more investor’s eyes landing on their ticker when reaching for the “buy” button.

More information about Cellceutix and their research can be found on their corporate website at

Let us hear your thoughts: Cellceutix Corp. Message Board

Cellceutix Corp. (CTIX.OB) Expedites Autism Studies in Response to Public Support; Announces Completion of Two Required Safety Pharmacology Studies

Monday, June 7th, 2010

Cellceutix Corp. was pleased to announce this morning its acknowledgement of the many emails, phone calls and letters received regarding KM-391, its novel compound for the treatment of autism. In response to the outcries, Cellceutix has drawn upon its many resources and expedited scheduling of additional pre-clinical studies of the compound with the results to be released in upcoming weeks.

Cellceutix worked with the world-renowned InterEd Faculty of Clinical Research (IFCR) in India to move rapidly in the development of KM-391. The Company’s President and Chief Scientific Officer, Dr. Krishna Menon, as Chancellor of IFCR, was able to request expedited scheduling for the testing of KM-391. The prestigious Cochin University of Science & Technology (CUSAT) agreed and conducted the testing. With the research completed and data undergoing analysis, results will soon be ready for release.

“Through a great collaborative effort between our team at Cellceutix with InterEd and Cochin University, we were able to reduce scheduling time from months to weeks,” stated George Evans, Chief Executive Officer of Cellceutix. “Our years of experience in the industry have provided us with valuable resources that were very supportive in our efforts to respond to the critical need for new autism treatments.”

Cellceutix previously reported that initial testing conducted with KM-391 on a mouse model has provided promising data. In a carefully conducted study, KM-391 was given orally over a three month period to groups of rats at two dosage levels. At each dosage level, KM-391 demonstrated significant improvements in the test animals when compared to both the “no treatment” group and the “active control” (fluoxetine) group on the parameters of brain plasticity, serotonin levels and behavioral function. Because KM-391 is a novel compound and not just a derivative of an existing compound, it has taken the spotlight within the autism community and the focus of many communications to Cellceutix regarding its development.

The company also announced today that it has completed two animal safety pharmacology studies for its cancer compound, Kevetrin™, both of which are required by the U.S. Food and Drug Administration (FDA) prior to filing an Investigational New Drug (IND) application. The studies evaluated the impact of the compound on the respiratory and central nervous systems of test animals. In the respiratory study, respiratory rate, tidal volume and minute volume were measured. In the central nervous system study, neuropharmacological effects and effects on body temperature were measured. A cardiovascular safety pharmacology study is nearing completion.

“The results of these studies are very encouraging for the further development of Kevetrin,” commented Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. “The respiratory and central nervous system studies showed no biologically significant changes compared to controls. Since these studies are required by the FDA for an IND filing, their completion is a major forward step for us.”

Let us hear your thoughts: Cellceutix Corp. Message Board

Cellceutix Corp. (CTIX.OB) CFO Partakes in Exclusive Interview to Discuss Autism Drug, Kevetrin(TM) and Various Progressions

Thursday, June 3rd, 2010

Cellceutix Corp. was pleased to announce that its Chief Financial Officer, Leo Ehrlich, has been featured in an interview with leading online financial publication, CEOCFO Interviews and News. Conducted by CEOCFO Senior Editor Lynn Fosse, the interview highlighted the distinctiveness of Cellceutix and the reasons why the company stands out from all other biotech companies in the industry.

Mr. Ehrlich discussed the progressions of KM-391, Cellceutix’s compound for the treatment of autism, and Kevetrin, which is being developed as a treatment for drug-resistant cancers. He also explained why their autism drug is revolutionary as there is no drug currently available for the treatment of autism. Additionally, Mr. Ehrlich discussed the company’s growth strategy as it relates to future potential partnerships, shareholder value and the strength of the Cellceutix management team.

“We are not dealing with just another cancer drug; we have indications that it is effective against drug-resistant cancers, which is a multibillion dollar market,” Mr. Ehrlich stated. “Most cancer drugs currently out there are just another variation of existing cancer drugs, whether they be another platinum based drug or another Taxol. We, however, have a completely new and novel compound.”

“We are pleased to have been interviewed by CEOCFO. The interview provides us another opportunity to showcase to our shareholders the many milestones we are achieving and the progressions of our business strategy,” commented Mr. Ehrlich.

The full interview can be found at the following link:

Let us hear your thoughts: Cellceutix Corp. Message Board

Cellceutix Corp. (CTIX.OB) is “One to Watch”

Wednesday, June 2nd, 2010

Cellceutix Corp., an emerging bio-pharmaceutical company, is in the early stages of receiving an influx of media attention and widespread notoriety within the pharmaceutical industry due to the promising results shown during the early development of a compound for the treatment of autism, KM-391, and the approaching Phase 1 clinical trials of Kevetrin™, the company’s compound for the treatment of drug-resistant cancers. In addition to these two, Cellceutix currently manages a portfolio of six other promising compounds.

KM-391, a 100% novel compound, is revolutionary in that it addresses the core issues of autism, unlike the pharmaceuticals presently on the market which merely treat the symptoms that result from autism. Preliminary testing of KM-391 revealed that test animals showed a significant increase in serotonin uptake compared to controls, with no apparent side-effects during long-term administration. Cellceutix is rapidly developing KM-391 in response to the public outcries received by the company since the results of early testing had been made publicly available.

Kevetrin, Cellceutix’s flagship product, is nearing Phase 1 clinical trials on humans with FDA regulated pre-clinical testing completed and the data being properly compiled for the IND application. While most cancer treatments today are derivatives of other compounds, Kevetrin is completely unique. Multidrug resistance, the principal mechanism by which strains of cancer develop resistance to chemotherapy drugs, is a major factor in the failure of many forms of chemotherapy today and represents a huge need for novel cancer treatments.

Kevetrin has been extensively studied in animal models of lung, breast, and colon cancers, targeting carcinoma strains that have proven resistant to standard therapies available on the market today with the results showing greater tumor growth delay than present therapies and strong efficacy in mouse models with increasing dosages. A successful drug for the treatment of drug-resistant cancers is purported to generate billions of dollars in annual revenues.

The Company has procured leading figures in the health and science arenas to lead its development efforts. The officers and advisors of Cellceutix include pioneers in the fields of cancer and genetics, as well as those who have been integral to mergers, acquisitions and the generation of exorbitant revenues through ground breaking therapies while holding high-level executive and research positions at industry giants such as Pfizer and Eli Lilly. Holding over a century of highly relevant experience in the pharmaceuticals industry, the team has been assembled with the specific goal of duplicating these past successes while revolutionizing much needed treatments for today’s most challenging diseases.

Let us hear your thoughts: Cellceutix Corp. Message Board